Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
bioMérieux-Pierre Fabre was a French healthcare conglomerate formed in 2001 through the merger of the Mérieux Alliance (the holding company for bioMérieux) and the Pierre Fabre Group. The merger was designed to create a global leader in theranostics, integrating in vitro diagnostics with pharmaceutical therapeutics to provide personalized medicine solutions. The group operated across three primary divisions: diagnostics, pharmaceuticals, and dermo-cosmetics. However, the strategic alliance was short-lived, and the two entities decided to demerge in 2004 to focus on their respective core competencies. Today, bioMérieux and Pierre Fabre operate as independent, world-class organizations in the diagnostics and pharmaceutical sectors, respectively.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on bioMérieux-Pierre Fabre.